Predictive value of serum PIVKA-Ⅱ miR-200a sTim-3 level for disease outcome in patients with hepatocellular carcinoma after chemotherapy
Objective To discuss the predictive value of serum PIVKA-Ⅱ,miR-200a,and sTim-3 levels on the outcome of liver cancer patients after chemotherapy.Methods Totally 60 patients with liver cancer who underwent chemotherapy at the Second Peoples Hospital of Luohe from February 2019 to February 2023,and divided them into a survival group of 43 ca-ses and a death group of 17 cases according to the outcome of the patients'diseases.patient's clinical data were compared.Detected the levels of serum PIVKA-Ⅱ,miR-200a,and sTim-3 in patients,Multifactor analysis and ROC curve were used to analyze the value of serum indexes in predicting the disease outcome of patients with liver cancer after chemotherapy.Re-sults There were no significant differences in age,gender,BMI,course of disease and family history of cancer between the two groups(P＞0.05).The smoking history,drinking history,tumor diameter,liver function Child-Pugh grade B,TNM stage Ⅲ,mixed liver cancer and lymph node metastasis in the survival group were significantly lower than those in the death group,and the difference was statistically significant(P＜0.05).The serum levels of PIVKA-Ⅱ and sTim-3 in survival group were significantly lower than those in death group,and the level of miR-200a was significantly higher than that in death group,with statistical significance(P＜0.05).High levels of PIVKA-Ⅱ and sTim-3 and low levels of miR-200a in serum were independent risk factors for disease outcome in patients with liver cancer after chemotherapy(P＜0.05).ROC a-nalysis results showed that the disease outcome AUC of PIVKA-Ⅱ,miR-200a and sTim-3 were 0.760,0.693 and 0.806,and the sensitivity was 75.56％,90.74％and 64.82％,respectively,for patients with liver cancer diagnosed by PIVKA-ii,Mir-200A and STIM-3 alone after chemotherapy.The specificity was 87.04％,86.30％and 87.04％,respectively.AUC was increased to 0.853,sensitivity and specificity were 79.63％and 81.48％,respectively.Conclusion Serum PIVKA-Ⅱ,miR-200a and sTim-3 can be used as predictive indicators of disease outcome after chemotherapy in patients with liver cancer,and the combined diagnosis is of high value.
Chemotherapy for liver cancerSerum indexDisease outcome
NETL
NSTL
万方数据
